玻璃体切除术联合术前眼内注射康柏西普在治疗增殖性糖尿病视网膜病变中的临床疗效  

Clinical efficacy of vitrectomy combined with preoperative intraocular injection of compacept in the treatment of proliferative diabetic retinopathy

作　　者：陶剑[1] Tao Jian(Department of Ophthalmology,the First People's Hospital of Changzhou,Changzhou Jiangsu 213000,China)

机构地区：[1]常州市第一人民医院眼科,江苏常州213000

出　　处：《生命科学仪器》2024年第2期180-182,共3页Life Science Instruments

摘　　要：目的探讨分析玻璃体切除术联合术前眼内注射康柏西普对增殖性糖尿病视网膜病变(DR)的临床疗效。方法选取常州市第一人民医院眼科2022年1月至2023年12月收治的80例增殖期DR患者(91眼)。按照随机数字表法分为2组,每组40例。对照组(46眼)仅单纯行玻璃体切除术,观察组(45眼)行玻璃体切除术联合康柏西普治疗。术前及术后1个月,比较两组眼部指标、术中及术后并发症发生情况。结果术后1个月,两组cRMT均低于术前,BCVA均高于术前,且观察组cRMT低于对照组,BCVA高于对照组,P<0.05。两组并发症发生率比较,P>0.05。结论玻璃体切除术联合术前眼内注射康柏西普治疗增殖性DR可明显改善患者视力,减轻黄斑水肿,安全有效。Objective:To explore and analyze the clinical effect of vitrectomy combined with preoperative intraocular injection of Compaxil on proliferative diabetic retinopathy(DR).Methods:Eighty patients(91 eyes)with proliferative DR admitted to the Department of Ophthalmology of Changzhou First People's Hospital from January 2022 to December 2023 were selected.According to the random number table method,they were divided into two groups,40 cases in each group.The control group(46 eyes)only underwent vitrectomy,while the observation group(45 eyes)underwent vitrectomy combined with Compaxip.Before operation and one month after operation,the eye indexes,intraoperative and postoperative complications were compared between the two groups.Results:One month after operation,cRMT was lower and BCVA was higher in both groups,while cRMT in observation group was lower and BCVA was higher than that in control group,P<0.05.The incidence of complications between the two groups was compared,P>0.05.Conclusion:Vitrectomy combined with preoperative intraocular injection of Compaxil can obviously improve the vision of patients with proliferative DR and reduce macular edema,which is safe and effective.

关 键 词：玻璃体切除术 康柏西普 增殖性糖尿病视网膜病变 

分 类 号：R774.1[医药卫生—眼科]